Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic ta...
Saved in:
Published in | Advanced biomedical research Vol. 8; no. 1; p. 63 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
India
Wolters Kluwer India Pvt. Ltd
01.01.2019
Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd Wolters Kluwer - Medknow Wolters Kluwer Medknow Publications |
Subjects | |
Online Access | Get full text |
ISSN | 2277-9175 2277-9175 |
DOI | 10.4103/abr.abr_142_19 |
Cover
Abstract | Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction. |
---|---|
AbstractList | Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction. Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction.Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction. |
Audience | Academic |
Author | Sanaei, Masumeh Kavoosi, Fraidoon |
AuthorAffiliation | From the Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran |
AuthorAffiliation_xml | – name: From the Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran |
Author_xml | – sequence: 1 givenname: Masumeh surname: Sanaei fullname: Sanaei, Masumeh organization: Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom – sequence: 2 givenname: Fraidoon surname: Kavoosi fullname: Kavoosi, Fraidoon organization: Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31737580$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1v0zAAxSM0xMbYlSOyxAUOLXEcf4TDpKrAVmkTEl9Xy3Hs1p1rD9uh7L_Hod26TluiKJH9e8_O83tZHDjvVFG8huW4hiX6INowzg-HdcVh86w4qipKRw2k-ODe92FxEuOyzBdhNcHNi-IQQYooZuVRsTw3MWVX8EkJqdKNFVFFIFwHHpkAM7cwrUk-xI_g0lsleysCuFRyIZyJqwi8BhOZjHfAOPBLBOP7CKbCSRXiq-K5Fjaqk-37uPj55fOP6fno4uvZbDq5GEkKsR0hhDQiZdcyzWpW0gohKlupKVSEaS1JhZHSrGtqCBnTTSsZ0Zg0UKim62CLjovZxrfzYsmvg1mJcMO9MPz_gA9zLkIy0irelQ3schhEtqyuCWmrTteMYIaJFliI7HW68bru25XqpHIpCLtnuj_jzILP_R9OGGoqirLBu61B8L97FRNfmSiVtcKpnA2vEMS4YgQO6NsH6NL3weWoBiqfJsSw2VFzkX_AOO3zunIw5RMCIa1KiHCmxo9Q-e7Uysh8rNrk8T3B-z1BZpL6m-aij5HPvn_bZ9_cD-UujdtW7VaXwccYlL5DYMmH5vKhtbvmZkH9QCBNEkOP8raNfVp2tpGtvU25YVe2X6vA856unF8_oeIE8W23-W230T9g7AtJ |
CitedBy_id | crossref_primary_10_3390_cancers15061647 crossref_primary_10_3389_fchem_2022_948217 crossref_primary_10_3389_fcell_2023_1224069 crossref_primary_10_1002_hep_32080 crossref_primary_10_1186_s12885_021_08595_w crossref_primary_10_3390_ijms22115516 crossref_primary_10_1016_j_biopha_2020_110454 crossref_primary_10_1111_cbdd_14366 crossref_primary_10_3390_ijms21217853 crossref_primary_10_3390_jpm12060964 crossref_primary_10_1002_cam4_5694 crossref_primary_10_1016_j_biopha_2022_112762 crossref_primary_10_1186_s13148_022_01370_z crossref_primary_10_3390_cells9030780 crossref_primary_10_1080_14728222_2023_2240021 crossref_primary_10_1038_s41392_021_00647_8 crossref_primary_10_1016_j_colsurfb_2020_111144 crossref_primary_10_1016_j_ejmech_2021_113824 crossref_primary_10_1016_j_mrrev_2021_108385 crossref_primary_10_1007_s11033_021_06481_z crossref_primary_10_3389_fcell_2021_719390 crossref_primary_10_1371_journal_pone_0316343 crossref_primary_10_1177_20406207241283277 crossref_primary_10_2174_0929867328666210901144658 crossref_primary_10_3389_fcell_2024_1426508 crossref_primary_10_3389_fbioe_2022_1047851 crossref_primary_10_4103_1735_5362_355214 crossref_primary_10_3892_or_2023_8480 crossref_primary_10_1016_j_bbamcr_2021_118966 crossref_primary_10_1016_j_ejmech_2022_115022 crossref_primary_10_3389_fonc_2022_853034 crossref_primary_10_3390_ph17050620 crossref_primary_10_3389_fonc_2021_741746 crossref_primary_10_4103_1735_5362_350240 crossref_primary_10_1002_cbdv_201900427 crossref_primary_10_1016_j_biopha_2020_110390 crossref_primary_10_3390_cells8121656 crossref_primary_10_1016_j_pharmthera_2024_108749 crossref_primary_10_1515_znc_2024_0140 crossref_primary_10_1016_j_intimp_2023_110428 crossref_primary_10_3389_fimmu_2022_882216 crossref_primary_10_2217_bmm_2020_0170 crossref_primary_10_3389_fonc_2022_1057186 crossref_primary_10_1080_14656566_2024_2331778 crossref_primary_10_3389_fcell_2020_576391 crossref_primary_10_3389_fcell_2020_00546 crossref_primary_10_1016_j_heliyon_2023_e23683 crossref_primary_10_2174_0929867325666181016163110 crossref_primary_10_1016_j_phrs_2021_105802 crossref_primary_10_3390_vaccines12060626 crossref_primary_10_1016_j_abb_2021_108776 crossref_primary_10_1080_17568919_2024_2437975 crossref_primary_10_1515_hsz_2021_0139 crossref_primary_10_1007_s40203_021_00077_y crossref_primary_10_3390_ijms21155582 crossref_primary_10_3390_cancers13153821 crossref_primary_10_1093_jambio_lxaf014 crossref_primary_10_3389_fgene_2021_767834 crossref_primary_10_1002_bit_28611 crossref_primary_10_3390_cancers13040634 crossref_primary_10_3390_cancers12041016 crossref_primary_10_3390_ijms23158141 crossref_primary_10_1111_cbdd_14239 crossref_primary_10_1186_s13148_022_01228_4 crossref_primary_10_1007_s10637_024_01479_3 crossref_primary_10_35366_97715 crossref_primary_10_3389_fgene_2023_1135404 crossref_primary_10_3389_fphys_2023_1332810 crossref_primary_10_1016_j_cbd_2020_100748 crossref_primary_10_3390_ph17040444 crossref_primary_10_1007_s00203_024_03834_7 crossref_primary_10_1016_j_arr_2021_101312 crossref_primary_10_1152_ajprenal_00405_2020 crossref_primary_10_1007_s12010_022_04107_z crossref_primary_10_2217_epi_2023_0181 crossref_primary_10_3390_cancers13112761 crossref_primary_10_1016_j_ejmech_2023_115613 |
Cites_doi | 10.1007/s10911-010-9166-0 10.1111/j.1464-410X.2009.08795.x 10.1073/pnas.0307708100 10.1038/sj.bjc.6604199 10.1038/cddis.2016.457 10.1371/journal.pgen.0020040 10.1586/14737140.7.4.583 10.2183/pjab.93.019 10.1016/j.surg.2004.05.018 10.1146/annurev.biochem.76.052705.162114 10.1016/j.cell.2012.06.013 10.1038/sj.onc.1210619 10.4161/cbt.7.4.5480 10.1002/jcb.20532 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7 10.1016/j.canlet.2013.07.022 10.1038/sj.cdd.4401567 10.3892/ijo.2015.3240 10.5483/BMBRep.2009.42.10.655 10.1155/2010/458431 10.1016/S0168-9525(03)00073-8 10.1002/cncr.20709 10.1111/j.1582-4934.2008.00436.x 10.3748/wjg.v13.i33.4458 10.1038/sj.onc.1210602 10.1371/journal.pone.0018087 10.5507/bp.2013.085 10.3390/molecules20033898 10.21037/tlcr.2016.02.02 10.1002/pmic.201000812 10.1593/neo.08474 10.3390/nu10060731 10.1158/1535-7163.MCT-08-0299 10.1200/JCO.2011.41.2395 10.1016/S1535-6108(04)00114-X 10.1097/MD.0000000000007663 10.1158/1078-0432.CCR-04-1092 10.4161/cbt.6.1.3549 10.1186/1472-6890-14-10 10.1038/sj.bjc.6603851 10.1038/nrc1779 10.4161/cbt.6.5.4007 10.1371/journal.pone.0064600 10.1016/j.lungcan.2005.02.006 10.4161/epi.3.6.7273 10.1007/s10549-004-1668-2 10.1093/jb/mvn074 10.1038/sj.onc.1207020 10.1158/0008-5472.CAN-06-0049 10.1002/ijc.25151 10.1186/s12943-018-0855-4 10.1093/emboj/21.11.2672 10.1371/journal.pone.0080657 10.1038/bjc.2016.36 10.1186/1471-2407-8-381 10.1186/1475-2867-11-29 10.1158/1078-0432.CCR-04-0455 10.1016/j.jhep.2012.01.018 10.1002/cbdv.200590118 10.1158/0008-5472.CAN-06-3996 10.1155/2010/923824 10.1016/j.bbamcr.2004.07.001 10.1158/1535-7163.1397.3.11 10.1200/JCO.2007.14.5730 10.1038/nbt1272 10.1038/cr.2011.22 10.1245/s10434-008-9940-z 10.1155/2016/8797206 10.1155/2011/315939 10.1111/j.1349-7006.2009.01387.x 10.2174/092986707782023299 10.1016/j.cell.2007.10.039 10.4161/auto.6.8.13365 10.1155/2015/243298 10.1186/1755-8794-2-67 10.1371/journal.pone.0002020 10.1080/1120009X.2016.1277007 10.1007/s00428-011-1103-0 10.1016/j.bbrc.2006.07.185 10.1158/1078-0432.CCR-07-0014 10.3748/wjg.v19.i6.813 10.1038/nrd2133 10.1371/journal.pone.0136193 10.1186/s12964-018-0231-4 10.1016/S0959-437X(00)00174-X 10.1158/1078-0432.CCR-08-1918 10.1128/MCB.00494-07 10.1016/j.semcancer.2007.04.001 10.1016/j.jhep.2017.03.026 10.1158/1078-0432.CCR-05-0259 |
ContentType | Journal Article |
Copyright | Copyright: © 2019 Advanced Biomedical Research. COPYRIGHT 2019 Medknow Publications and Media Pvt. Ltd. 2019. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright: © 2019 Advanced Biomedical Research 2019 |
Copyright_xml | – notice: Copyright: © 2019 Advanced Biomedical Research. – notice: COPYRIGHT 2019 Medknow Publications and Media Pvt. Ltd. – notice: 2019. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright: © 2019 Advanced Biomedical Research 2019 |
DBID | AAYXX CITATION NPM ISR 3V. 7X7 7XB 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AFKRA AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. L6V LK8 M0S M7P M7S PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS PTHSS 7X8 5PM DOA |
DOI | 10.4103/abr.abr_142_19 |
DatabaseName | CrossRef PubMed Gale In Context: Science ProQuest Central (Corporate) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection Biological Sciences ProQuest Health & Medical Collection Biological Science Database Engineering Database (subscription) Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Engineering Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) Engineering Collection Engineering Database ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Materials Science & Engineering Collection ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2277-9175 |
EndPage | 63 |
ExternalDocumentID | oai_doaj_org_article_d091d3176cb84466b2df4865856fa5aa PMC6839273 A611720135 31737580 10_4103_abr_abr_142_19 10.4103/abr.abr_142_19_63_Histone Deacetyl |
Genre | Journal Article Review |
GeographicLocations | Iran |
GeographicLocations_xml | – name: Iran |
GroupedDBID | 5VS 7X7 8FE 8FG 8FH 8FI 8FJ AAKDD ABJCF ABUWG ACGFS ACIWK ACPRK ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI CCPQU DIK FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HMCUK HYE IAO IHR ISR ITC KQ8 L6V LK8 M48 M7P M7S M~E OK1 OVD PGMZT PHGZM PHGZT PIMPY PROAC PTHSS RMW RNS RPM TEORI UKHRP W3E AAYXX CITATION EMOBN IPNFZ RIG NPM PMFND 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c715l-333f360db8f848072337cbcf71e68ffc6253ef8d941188f9bc86f5691ae9dd1b3 |
IEDL.DBID | M48 |
ISSN | 2277-9175 |
IngestDate | Wed Aug 27 01:14:05 EDT 2025 Thu Aug 21 18:20:59 EDT 2025 Fri Sep 05 08:35:49 EDT 2025 Fri Jul 25 11:54:43 EDT 2025 Tue Jun 17 20:59:21 EDT 2025 Tue Jun 10 20:27:55 EDT 2025 Fri Jun 27 04:25:31 EDT 2025 Thu Apr 03 06:59:01 EDT 2025 Thu Apr 24 23:11:56 EDT 2025 Tue Jul 01 03:12:12 EDT 2025 Tue Jun 17 22:50:30 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | histone deacetylase Cancer histone deacetylase inhibitors |
Language | English |
License | http://creativecommons.org/licenses/by-nc-sa/4.0 Copyright: © 2019 Advanced Biomedical Research. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c715l-333f360db8f848072337cbcf71e68ffc6253ef8d941188f9bc86f5691ae9dd1b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
OpenAccessLink | https://doaj.org/article/d091d3176cb84466b2df4865856fa5aa |
PMID | 31737580 |
PQID | 2312771519 |
PQPubID | 2035645 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_d091d3176cb84466b2df4865856fa5aa pubmedcentral_primary_oai_pubmedcentral_nih_gov_6839273 proquest_miscellaneous_2315528613 proquest_journals_2312771519 gale_infotracmisc_A611720135 gale_infotracacademiconefile_A611720135 gale_incontextgauss_ISR_A611720135 pubmed_primary_31737580 crossref_primary_10_4103_abr_abr_142_19 crossref_citationtrail_10_4103_abr_abr_142_19 wolterskluwer_medknow_10_4103_abr_abr_142_19_63_Histone_Deacetyl |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-1-1-01 |
PublicationDateYYYYMMDD | 2019-01-01 |
PublicationDate_xml | – month: 01 year: 2019 text: 2019-1-1-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | India |
PublicationPlace_xml | – name: India – name: Mumbai |
PublicationTitle | Advanced biomedical research |
PublicationTitleAlternate | Adv Biomed Res |
PublicationYear | 2019 |
Publisher | Wolters Kluwer India Pvt. Ltd Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd Wolters Kluwer - Medknow Wolters Kluwer Medknow Publications |
Publisher_xml | – name: Wolters Kluwer India Pvt. Ltd – name: Medknow Publications and Media Pvt. Ltd – name: Medknow Publications & Media Pvt. Ltd – name: Wolters Kluwer - Medknow – name: Wolters Kluwer Medknow Publications |
References | Kato (key-10.4103/2277-9175.270133-28) 2007 Baradari (key-10.4103/2277-9175.270133-79) 2007 Bai (key-10.4103/2277-9175.270133-87) 2006 Dawson (key-10.4103/2277-9175.270133-14) 2012 Jakopovic (key-10.4103/2277-9175.270133-92) 2013 Kavoosi (key-10.4103/2277-9175.270133-9) 2018 Sanaei (key-10.4103/2277-9175.270133-11) 2017 Hodawadekar (key-10.4103/2277-9175.270133-21) 2007 Hrabeta (key-10.4103/2277-9175.270133-6) 2014 Chopin (key-10.4103/2277-9175.270133-35) 2004 Asgar (key-10.4103/2277-9175.270133-81) 2016 Weichert (key-10.4103/2277-9175.270133-46) 2008 Cao (key-10.4103/2277-9175.270133-93) 2017 Cha (key-10.4103/2277-9175.270133-30) 2009 LaBonte (key-10.4103/2277-9175.270133-72) 2009 Stypula-Cyrus (key-10.4103/2277-9175.270133-70) 2013 Rizvi (key-10.4103/2277-9175.270133-78) 2017 Shahbazian (key-10.4103/2277-9175.270133-13) 2007 Liu (key-10.4103/2277-9175.270133-76) 2010 Doi (key-10.4103/2277-9175.270133-98) 2004 Yin (key-10.4103/2277-9175.270133-80) 2017 Allis (key-10.4103/2277-9175.270133-4) 2007 Bartling (key-10.4103/2277-9175.270133-95) 2005 Takai (key-10.4103/2277-9175.270133-52) 2004 Zhang (key-10.4103/2277-9175.270133-84) 2015 Wang (key-10.4103/2277-9175.270133-29) 2005 Zhou (key-10.4103/2277-9175.270133-65) 2007 Poyet (key-10.4103/2277-9175.270133-31) 2014 Waltregny (key-10.4103/2277-9175.270133-40) 2004 Quint (key-10.4103/2277-9175.270133-73) 2011 Hull (key-10.4103/2277-9175.270133-7) 2016 Firestein (key-10.4103/2277-9175.270133-17) 2008 Rundall (key-10.4103/2277-9175.270133-99) 2004 Gui (key-10.4103/2277-9175.270133-34) 2004 Weichert (key-10.4103/2277-9175.270133-41) 2008 Takai (key-10.4103/2277-9175.270133-53) 2007 Khochbin (key-10.4103/2277-9175.270133-2) 2001 Cuppens (key-10.4103/2277-9175.270133-54) 2015 key-10.4103/2277-9175.270133-10 key-10.4103/2277-9175.270133-12 key-10.4103/2277-9175.270133-94 Feng (key-10.4103/2277-9175.270133-58) 2013 Ouaïssi (key-10.4103/2277-9175.270133-88) 2008 Abbas (key-10.4103/2277-9175.270133-44) 2008 Ozawa (key-10.4103/2277-9175.270133-33) 2010 Dashwood (key-10.4103/2277-9175.270133-69) 2007 Bannister (key-10.4103/2277-9175.270133-23) 2011 Jones (key-10.4103/2277-9175.270133-36) 2009 Mottamal (key-10.4103/2277-9175.270133-26) 2015 Zhu (key-10.4103/2277-9175.270133-68) 2004 Yoshida (key-10.4103/2277-9175.270133-1) 2017 Pathiraja (key-10.4103/2277-9175.270133-67) 2010 Fritzsche (key-10.4103/2277-9175.270133-27) 2008 Yamaguchi (key-10.4103/2277-9175.270133-82) 2010 Kim (key-10.4103/2277-9175.270133-19) 2011 Zhang (key-10.4103/2277-9175.270133-25) 2013 Takai (key-10.4103/2277-9175.270133-56) 2010 Nakagawa (key-10.4103/2277-9175.270133-39) 2007 Marks (key-10.4103/2277-9175.270133-83) 2007 Takai (key-10.4103/2277-9175.270133-49) 2010 Chen (key-10.4103/2277-9175.270133-42) 2007 Liu (key-10.4103/2277-9175.270133-74) 2013 Siu (key-10.4103/2277-9175.270133-24) 2008 Parthun (key-10.4103/2277-9175.270133-22) 2007 Kitamura (key-10.4103/2277-9175.270133-85) 2012 Senese (key-10.4103/2277-9175.270133-16) 2007 Ceccacci (key-10.4103/2277-9175.270133-8) 2016 Krusche (key-10.4103/2277-9175.270133-61) 2005 Ouaïssi (key-10.4103/2277-9175.270133-89) 2011 Koutsounas (key-10.4103/2277-9175.270133-90) 2013 Chou (key-10.4103/2277-9175.270133-71) 2011 Marchion (key-10.4103/2277-9175.270133-55) 2007 Minucci (key-10.4103/2277-9175.270133-63) 2006 Zhang (key-10.4103/2277-9175.270133-62) 2004 Cacan (key-10.4103/2277-9175.270133-47) 2017 Moore (key-10.4103/2277-9175.270133-91) 2004 Hayashi (key-10.4103/2277-9175.270133-48) 2010 Wild (key-10.4103/2277-9175.270133-32) 2005 Dokmanovic (key-10.4103/2277-9175.270133-64) 2005 Ansari (key-10.4103/2277-9175.270133-96) 2016 Ouaïssi (key-10.4103/2277-9175.270133-86) 2008 Jones (key-10.4103/2277-9175.270133-3) 2011 Geng (key-10.4103/2277-9175.270133-97) 2006 Lagger (key-10.4103/2277-9175.270133-38) 2002 Yeo (key-10.4103/2277-9175.270133-77) 2012 Weberpals (key-10.4103/2277-9175.270133-50) 2011 Pruitt (key-10.4103/2277-9175.270133-66) 2006 Muscolini (key-10.4103/2277-9175.270133-51) 2008 Cress (key-10.4103/2277-9175.270133-15) 2000 Atmaca (key-10.4103/2277-9175.270133-60) 2007 Khabele (key-10.4103/2277-9175.270133-45) 2007 Jung (key-10.4103/2277-9175.270133-43) 2005 Yang (key-10.4103/2277-9175.270133-20) 2018 Bolden (key-10.4103/2277-9175.270133-5) 2006 Sami (key-10.4103/2277-9175.270133-37) 2008 Vanaja (key-10.4103/2277-9175.270133-57) 2018 Verdin (key-10.4103/2277-9175.270133-18) 2003 Huang (key-10.4103/2277-9175.270133-59) 2005 Kim (key-10.4103/2277-9175.270133-75) 2009 |
References_xml | – start-page: 35 year: 2010 ident: key-10.4103/2277-9175.270133-67 article-title: Epigenetic regulation in estrogen receptor positive breast cancer – Role in treatment response publication-title: J Mammary Gland Biol Neoplasia doi: 10.1007/s10911-010-9166-0 – start-page: 273 year: 2004 ident: key-10.4103/2277-9175.270133-40 article-title: Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells publication-title: Eur J Histochem – start-page: 1181 year: 2010 ident: key-10.4103/2277-9175.270133-33 article-title: Inhibition of bladder tumour growth by histone deacetylase inhibitor publication-title: BJU Int doi: 10.1111/j.1464-410X.2009.08795.x – start-page: 1241 year: 2004 ident: key-10.4103/2277-9175.270133-34 article-title: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0307708100 – start-page: 604 year: 2008 ident: key-10.4103/2277-9175.270133-41 article-title: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604199 – start-page: e2856 year: 2017 ident: key-10.4103/2277-9175.270133-80 article-title: Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition publication-title: Cell Death Dis doi: 10.1038/cddis.2016.457 – start-page: e40 year: 2006 ident: key-10.4103/2277-9175.270133-66 article-title: Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation publication-title: PLoS Genet doi: 10.1371/journal.pgen.0020040 – start-page: 583 year: 2007 ident: key-10.4103/2277-9175.270133-55 article-title: Development of histone deacetylase inhibitors for cancer treatment publication-title: Expert Rev Anticancer Ther doi: 10.1586/14737140.7.4.583 – start-page: 297 year: 2017 ident: key-10.4103/2277-9175.270133-1 article-title: Chemical and structural biology of protein lysine deacetylases publication-title: Proc Jpn Acad Ser B Phys Biol Sci doi: 10.2183/pjab.93.019 – start-page: 416 year: 2004 ident: key-10.4103/2277-9175.270133-99 article-title: Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death publication-title: Surgery doi: 10.1016/j.surg.2004.05.018 – start-page: 75 year: 2007 ident: key-10.4103/2277-9175.270133-13 article-title: Functions of site-specific histone acetylation and deacetylation publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.76.052705.162114 – start-page: 12 year: 2012 ident: key-10.4103/2277-9175.270133-14 article-title: Cancer epigenetics: From mechanism to therapy publication-title: Cell doi: 10.1016/j.cell.2012.06.013 – start-page: 5528 year: 2007 ident: key-10.4103/2277-9175.270133-21 article-title: Chemistry of acetyl transfer by histone modifying enzymes: Structure, mechanism and implications for effector design publication-title: Oncogene doi: 10.1038/sj.onc.1210619 – start-page: 523 year: 2008 ident: key-10.4103/2277-9175.270133-88 article-title: Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors publication-title: Cancer Biol Ther doi: 10.4161/cbt.7.4.5480 – start-page: 293 year: 2005 ident: key-10.4103/2277-9175.270133-64 article-title: Prospects: Histone deacetylase inhibitors publication-title: J Cell Biochem doi: 10.1002/jcb.20532 – start-page: 1 year: 2000 ident: key-10.4103/2277-9175.270133-15 article-title: Histone deacetylases, transcriptional control, and cancer publication-title: J Cell Physiol doi: 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7 – start-page: 60 year: 2013 ident: key-10.4103/2277-9175.270133-74 article-title: Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.07.022 – start-page: 395 year: 2005 ident: key-10.4103/2277-9175.270133-59 article-title: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4401567 – start-page: 409 year: 2016 ident: key-10.4103/2277-9175.270133-81 article-title: Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines publication-title: Int J Oncol doi: 10.3892/ijo.2015.3240 – start-page: 655 year: 2009 ident: key-10.4103/2277-9175.270133-75 article-title: Anti-invasive activity of histone deacetylase inhibitors via the induction of egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells publication-title: BMB Rep doi: 10.5483/BMBRep.2009.42.10.655 – start-page: 1 year: 2010 ident: key-10.4103/2277-9175.270133-49 article-title: Histone deacetylase inhibitor therapy in epithelial ovarian cancer publication-title: J Oncol doi: 10.1155/2010/458431 – start-page: 286 year: 2003 ident: key-10.4103/2277-9175.270133-18 article-title: Class II histone deacetylases: Versatile regulators publication-title: Trends Genet doi: 10.1016/S0168-9525(03)00073-8 – start-page: 2760 year: 2004 ident: key-10.4103/2277-9175.270133-52 article-title: Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis publication-title: Cancer doi: 10.1002/cncr.20709 – start-page: 2376 year: 2009 ident: key-10.4103/2277-9175.270133-36 article-title: The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinomain vitro and in vivo publication-title: J Cell Mol Med doi: 10.1111/j.1582-4934.2008.00436.x – start-page: 4458 year: 2007 ident: key-10.4103/2277-9175.270133-79 article-title: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells publication-title: World J Gastroenterol doi: 10.3748/wjg.v13.i33.4458 – start-page: 5319 year: 2007 ident: key-10.4103/2277-9175.270133-22 article-title: Hat1: The emerging cellular roles of a type B histone acetyltransferase publication-title: Oncogene doi: 10.1038/sj.onc.1210602 – start-page: e18087 year: 2011 ident: key-10.4103/2277-9175.270133-71 article-title: HDAC inhibition decreases the expression of EGFR in colorectal cancer cells publication-title: PLoS One doi: 10.1371/journal.pone.0018087 – start-page: 161 year: 2014 ident: key-10.4103/2277-9175.270133-6 article-title: Histone deacetylase inhibitors in cancer therapy.A review publication-title: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub doi: 10.5507/bp.2013.085 – start-page: 3898 year: 2015 ident: key-10.4103/2277-9175.270133-26 article-title: Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents publication-title: Molecules doi: 10.3390/molecules20033898 – start-page: 155 year: 2016 ident: key-10.4103/2277-9175.270133-96 article-title: Epigenetics in non-small cell lung cancer: From basics to therapeutics publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr.2016.02.02 – start-page: 3012 year: 2011 ident: key-10.4103/2277-9175.270133-3 article-title: Protein acetylation in prokaryotes publication-title: Proteomics doi: 10.1002/pmic.201000812 – start-page: 1021 year: 2008 ident: key-10.4103/2277-9175.270133-46 article-title: Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas publication-title: Neoplasia doi: 10.1593/neo.08474 – ident: key-10.4103/2277-9175.270133-12 doi: 10.3390/nu10060731 – start-page: 1410 year: 2008 ident: key-10.4103/2277-9175.270133-51 article-title: Trichostatin A up-regulates p73 and induces bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-08-0299 – start-page: 3361 year: 2012 ident: key-10.4103/2277-9175.270133-77 article-title: Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the mayo phase II consortium and the cancer therapeutics research group publication-title: J Clin Oncol doi: 10.1200/JCO.2011.41.2395 – start-page: 455 year: 2004 ident: key-10.4103/2277-9175.270133-68 article-title: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis publication-title: Cancer Cell doi: 10.1016/S1535-6108(04)00114-X – start-page: e7663 year: 2017 ident: key-10.4103/2277-9175.270133-93 article-title: Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000007663 – start-page: 3535 year: 2005 ident: key-10.4103/2277-9175.270133-29 article-title: Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-1092 – start-page: 64 year: 2007 ident: key-10.4103/2277-9175.270133-65 article-title: Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation publication-title: Cancer Biol Ther doi: 10.4161/cbt.6.1.3549 – start-page: 10 year: 2014 ident: key-10.4103/2277-9175.270133-31 article-title: Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer publication-title: BMC Clin Pathol doi: 10.1186/1472-6890-14-10 – start-page: 177 year: 2007 ident: key-10.4103/2277-9175.270133-60 article-title: Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603851 – start-page: 38 year: 2006 ident: key-10.4103/2277-9175.270133-63 article-title: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc1779 – start-page: 795 year: 2007 ident: key-10.4103/2277-9175.270133-45 article-title: Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy publication-title: Cancer Biol Ther doi: 10.4161/cbt.6.5.4007 – start-page: e64600 year: 2013 ident: key-10.4103/2277-9175.270133-70 article-title: HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure publication-title: PLoS One doi: 10.1371/journal.pone.0064600 – start-page: 145 year: 2005 ident: key-10.4103/2277-9175.270133-95 article-title: Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma publication-title: Lung Cancer doi: 10.1016/j.lungcan.2005.02.006 – start-page: 769 year: 2007 ident: key-10.4103/2277-9175.270133-39 article-title: Expression profile of class I histone deacetylases in human cancer tissues publication-title: Oncol Rep – start-page: 300 year: 2008 ident: key-10.4103/2277-9175.270133-44 article-title: The role of histone deacetylases in prostate cancer publication-title: Epigenetics doi: 10.4161/epi.3.6.7273 – start-page: 15 year: 2005 ident: key-10.4103/2277-9175.270133-61 article-title: Histone deacetylase-1 and -3 protein expression in human breast cancer: A tissue microarray analysis publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-004-1668-2 – start-page: 357 year: 2008 ident: key-10.4103/2277-9175.270133-37 article-title: Valproic acid inhibits the growth of cervical cancer bothin vitro and in vivo publication-title: J Biochem doi: 10.1093/jb/mvn074 – start-page: 21 year: 2004 ident: key-10.4103/2277-9175.270133-35 article-title: P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells publication-title: Oncogene doi: 10.1038/sj.onc.1207020 – start-page: 11298 year: 2006 ident: key-10.4103/2277-9175.270133-97 article-title: Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-0049 – start-page: 1332 year: 2010 ident: key-10.4103/2277-9175.270133-48 article-title: Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin publication-title: Int J Cancer doi: 10.1002/ijc.25151 – start-page: 109 year: 2018 ident: key-10.4103/2277-9175.270133-20 article-title: Epigenetics in ovarian cancer: Premise, properties, and perspectives publication-title: Mol Cancer doi: 10.1186/s12943-018-0855-4 – start-page: 2672 year: 2002 ident: key-10.4103/2277-9175.270133-38 article-title: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression publication-title: EMBO J doi: 10.1093/emboj/21.11.2672 – start-page: e80657 year: 2013 ident: key-10.4103/2277-9175.270133-58 article-title: Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model publication-title: PLoS One doi: 10.1371/journal.pone.0080657 – start-page: 261 year: 2013 ident: key-10.4103/2277-9175.270133-92 article-title: Targeting the epigenome in lung cancer: Expanding approaches to epigenetic therapy publication-title: Front Oncol – start-page: 605 year: 2016 ident: key-10.4103/2277-9175.270133-8 article-title: Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia publication-title: Br J Cancer doi: 10.1038/bjc.2016.36 – start-page: 381 year: 2008 ident: key-10.4103/2277-9175.270133-27 article-title: Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer publication-title: BMC Cancer doi: 10.1186/1471-2407-8-381 – start-page: 29 year: 2011 ident: key-10.4103/2277-9175.270133-50 article-title: The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells publication-title: Cancer Cell Int doi: 10.1186/1475-2867-11-29 – start-page: 6962 year: 2004 ident: key-10.4103/2277-9175.270133-62 article-title: HDAC6 expression is correlated with better survival in breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0455 – start-page: 84 year: 2012 ident: key-10.4103/2277-9175.270133-85 article-title: The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice publication-title: J Hepatol doi: 10.1016/j.jhep.2012.01.018 – start-page: 1452 year: 2005 ident: key-10.4103/2277-9175.270133-43 article-title: Rational design and development of radiation-sensitizing histone deacetylase inhibitors publication-title: Chem Biodivers doi: 10.1002/cbdv.200590118 – start-page: 5318 year: 2007 ident: key-10.4103/2277-9175.270133-42 article-title: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting ku70 acetylation publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3996 – start-page: 1 year: 2010 ident: key-10.4103/2277-9175.270133-56 article-title: Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer publication-title: Obstet Gynecol Int doi: 10.1155/2010/923824 – start-page: 167 year: 2004 ident: key-10.4103/2277-9175.270133-91 article-title: Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamcr.2004.07.001 – start-page: 1397 year: 2004 ident: key-10.4103/2277-9175.270133-98 article-title: The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.1397.3.11 – start-page: 1940 year: 2008 ident: key-10.4103/2277-9175.270133-24 article-title: Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.5730 – start-page: 84 year: 2007 ident: key-10.4103/2277-9175.270133-83 article-title: Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug publication-title: Nat Biotechnol doi: 10.1038/nbt1272 – start-page: 381 year: 2011 ident: key-10.4103/2277-9175.270133-23 article-title: Regulation of chromatin by histone modifications publication-title: Cell Res doi: 10.1038/cr.2011.22 – start-page: 2318 year: 2008 ident: key-10.4103/2277-9175.270133-86 article-title: High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas publication-title: Ann Surg Oncol doi: 10.1245/s10434-008-9940-z – start-page: 1 year: 2016 ident: key-10.4103/2277-9175.270133-7 article-title: HDAC inhibitors as epigenetic regulators of the immune system: Impacts on cancer therapy and inflammatory diseases publication-title: Biomed Res Int doi: 10.1155/2016/8797206 – start-page: 733 year: 2013 ident: key-10.4103/2277-9175.270133-25 article-title: Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors publication-title: Onco Targets Ther – start-page: 1 year: 2011 ident: key-10.4103/2277-9175.270133-89 article-title: Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer publication-title: J Biomed Biotechnol doi: 10.1155/2011/315939 – start-page: 355 year: 2010 ident: key-10.4103/2277-9175.270133-82 article-title: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2009.01387.x – ident: key-10.4103/2277-9175.270133-94 – start-page: 2548 year: 2007 ident: key-10.4103/2277-9175.270133-53 article-title: Human endometrial and ovarian cancer cells: Histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis publication-title: Curr Med Chem doi: 10.2174/092986707782023299 – start-page: 633 year: 2007 ident: key-10.4103/2277-9175.270133-4 article-title: New nomenclature for chromatin-modifying enzymes publication-title: Cell doi: 10.1016/j.cell.2007.10.039 – start-page: 1057 year: 2010 ident: key-10.4103/2277-9175.270133-76 article-title: Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma publication-title: Autophagy doi: 10.4161/auto.6.8.13365 – start-page: 1 year: 2015 ident: key-10.4103/2277-9175.270133-54 article-title: Potential therapeutic targets in uterine sarcomas publication-title: Sarcoma doi: 10.1155/2015/243298 – start-page: 67 year: 2009 ident: key-10.4103/2277-9175.270133-72 article-title: DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines publication-title: BMC Med Genomics doi: 10.1186/1755-8794-2-67 – start-page: 163 issn: 2277-9175 year: 2017 ident: key-10.4103/2277-9175.270133-11 article-title: Effect of genistein and 17-β estradiol on the viability and apoptosis of human hepatocellular carcinoma hepG2 cell line publication-title: Adv Biomed Res – start-page: e2020 year: 2008 ident: key-10.4103/2277-9175.270133-17 article-title: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth publication-title: PLoS One doi: 10.1371/journal.pone.0002020 – start-page: 166 year: 2011 ident: key-10.4103/2277-9175.270133-19 article-title: Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs publication-title: Am J Transl Res – start-page: 173 year: 2017 ident: key-10.4103/2277-9175.270133-47 article-title: Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells publication-title: J Chemother doi: 10.1080/1120009X.2016.1277007 – start-page: 129 year: 2011 ident: key-10.4103/2277-9175.270133-73 article-title: Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC publication-title: Virchows Arch doi: 10.1007/s00428-011-1103-0 – start-page: 1245 year: 2006 ident: key-10.4103/2277-9175.270133-87 article-title: Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2006.07.185 – start-page: 4538 year: 2007 ident: key-10.4103/2277-9175.270133-28 article-title: Synergisticin vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-0014 – start-page: 813 year: 2013 ident: key-10.4103/2277-9175.270133-90 article-title: Current evidence for histone deacetylase inhibitors in pancreatic cancer publication-title: World J Gastroenterol doi: 10.3748/wjg.v19.i6.813 – start-page: 12 year: 2018 ident: key-10.4103/2277-9175.270133-9 article-title: Comparative analysis of the effects of valproic acid and tamoxifen on proliferation, and apoptosis of human hepatocellular carcinoma WCH 17 celllin publication-title: Iran J Peadiatr Hematol Oncol – start-page: 769 year: 2006 ident: key-10.4103/2277-9175.270133-5 article-title: Anticancer activities of histone deacetylase inhibitors publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2133 – ident: key-10.4103/2277-9175.270133-10 – start-page: e0136193 year: 2015 ident: key-10.4103/2277-9175.270133-84 article-title: Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling publication-title: PLoS One doi: 10.1371/journal.pone.0136193 – start-page: 20 year: 2018 ident: key-10.4103/2277-9175.270133-57 article-title: Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6 publication-title: Cell Commun Signal doi: 10.1186/s12964-018-0231-4 – start-page: 162 year: 2001 ident: key-10.4103/2277-9175.270133-2 article-title: Functional significance of histone deacetylase diversity publication-title: Curr Opin Genet Dev doi: 10.1016/S0959-437X(00)00174-X – start-page: 840 year: 2009 ident: key-10.4103/2277-9175.270133-30 article-title: Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1918 – start-page: 4784 year: 2007 ident: key-10.4103/2277-9175.270133-16 article-title: Role for histone deacetylase 1 in human tumor cell proliferation publication-title: Mol Cell Biol doi: 10.1128/MCB.00494-07 – start-page: 363 year: 2007 ident: key-10.4103/2277-9175.270133-69 article-title: Dietary histone deacetylase inhibitors: From cells to mice to man publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2007.04.001 – start-page: 632 year: 2017 ident: key-10.4103/2277-9175.270133-78 article-title: Emerging molecular therapeutic targets for cholangiocarcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2017.03.026 – start-page: 4415 year: 2005 ident: key-10.4103/2277-9175.270133-32 article-title: Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0259 |
SSID | ssj0000684659 |
Score | 2.4099095 |
SecondaryResourceType | review_article |
Snippet | Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs)... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref wolterskluwer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 63 |
SubjectTerms | Acetylation Angiogenesis Apoptosis Biochemistry Cancer Cancer cells Carcinogenesis Carcinogens Cell cycle Cell death Cell differentiation Classification Deacetylation Deoxyribonucleic acid Development and progression Differentiation (biology) DNA DNA methylation Enzymes Epigenetic inheritance Epigenetics Fatty acids Gene expression Genes Histone deacetylase histone deacetylase inhibitors Histones Immune system Inhibitors Lung cancer Molecular modelling Peptides Proteins Review Romidepsin Therapeutic applications Tumorigenesis Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQDwgJIb4JFGQQEqfQJHYchxNLoWqRlgNQ1JsVf9FAm0XrXSH-PTNOdkmAiguHvaxnV_bMi-dNbD8T8jRjlpc156l1NU-5rXQqATppYaQ2UB9YHdX25-_E4TF_e1KejK76wj1hvTxw77g9CwnNQpITRktce9SF9VxC3iyFb8omUqOszkbFVD8HQ16NN6UVcY0SkmSv2MjzjO01evkcPkB7C4USO6OMFIX7_5yeR_np972TV78vcF07fI3b2kfJ6eA6uTawSjrrR3ODXHLdTXJ5Pqyb3yJfohpI5-hrmAHd6gdQZhdo01n6lwZ61J22usVreF7Q-eb6XDp3eEi4DeeBLjydxfMQtO3oJ6i2F-tA9xE_y3CbHB-8-bh_mA63LKSmysuzlDHmmcisll7i-fKCscpo46vcCem9gQKJOS9tzaEWkb7WRgpfijpvXG1trtkdstNBR-8RCnGxFdRvQnjDPUylVV5k0gDDbKTnNk9IuvG0MoMEOd6EcaagFMHIKIzKr8gk5NnW_lsvvnGh5SsM3NYKRbPjFwAlNUBJ_QtKCXmCYVcoi9HhvpvPzToEdfThvZqJHJge0OUS-jQY-QX03TTDMQbwACppTSx3J5bw3Jpp8wZdapg3ggK2DXgFFgYjerxtxl_iXrjOQTjRpiwLCTwsIXd7MG7HDaNjUAFmCakmMJ04ZtrStadRVVwgVa7gP19OAK3O-2OZFzheCaYGpKoNUu__j2A8IFfATXX_tmuX7KyWa_cQ-N9KP4qP-k_eG1iG priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdGJyEkhPgmMJBBSDyFJbHjOEgIurFpQ-qEBkN7s-KvrbAlo2mF-O-5y0fXAOOhL_W1ss_n8-9s3-8IeRkxy9Oc89C6nIfcZjqUYDphYqQ2EB9Y3bDtTw7E3hH_eJwer5GDPhcGn1X2PrFx1LYyeEa-CTgkyTLYn_J3Fz9CrBqFt6t9CY2iK61g3zYUY9fIOrjkNBqR9a2dg0-Hy1OXSMB-m-YteyOPI7ZZ6Nlr-AAEThTS7azsTg2J_9-uemWv-vMd5c2fFd5x19-bJ-4rG9XubXKrQ5h03JrEHbLmyrvk-qS7Q79HvjXMIKWjH8AbuvkvgM-upkVp6T8a6H55OtVTLMnzhk76Urp04jBheFqf17TydNzkRtBpSb9C5F0tarqNtjSr75Oj3Z0v23thV3EhNKDas5Ax5pmIrJZeYq55wlhmtPFZ7IT03kCwxJyXNucQl0ifayOFT0UeFy63NtbsARmV0NFHhHIpbAaxnBDecA9uNYuTSBpAm4X03MYBCXtNK9PRkWNVjDMFYQnOjMJZuZyZgLxayl-0RBxXSm7hxC2lkEC7-aKanahuPSoLOMkCdhJGS7zS1on10GUInoQv0qIIyAucdoUUGSW-wTkpFnWt9j8fqrGIAfUBdE6hT52Qr6DvpuhSGkADyKo1kNwYSMIaNsPm3rpU50NqdWnxAXm-bMZf4ru40sF0okyaJhIwWUAetsa4HDeMjkE0GAUkG5jpQDHDlnJ62jCMC4TNGfzn-4FBq_M2RfMKxSvBVGepqrfUx_8f2RNyAxSQt2daG2Q0ny3cU0B5c_2sW7q_ASZMVN8 priority: 102 providerName: ProQuest – databaseName: Medknow Open Access Journals dbid: W3E link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLamISEkhLgvMJBBSDwFkjhxHCIkymDakMoDY7A3y9ctsCWoaUH79xw7btcAe-KhUlWfJva52N_x5TNCzxKi86LK81ibKo9zXcqYgevEmWJSQX6gpWfbn36ke4f5h6PiaAMt1nZVCv1TNh0kmz45Dwr0x7p8WGR-0RFGvfocfMHN8VV1iGRWh8rWQzRSUpvlF7EANDp_fSBaYZraMxJBpn8lK9PKBcNXcjE1k1AYlP01a6t3DXSPeZqQl0LOXsAHMHPGHT_P2nDmWf__7tvXBrc_N15e_9W5RfH-u98Tvzay7d5ENwIkxZNBBbfQhmlvo6vTsOh-B33zVCKtwe-g-zTzc2ih6bFoNf5HAd5vTxrZuDt8XuHp8u5dPDXuhHHTn_W4s3jiD1PgpsVfIFXvFj3ecc436--iw933n3f24nBFQ6zKtDiNCSGW0ERLZpk7nJ4RUiqpbJkayqxVkF0RY5muckhkmK2kYtQWtEqFqbROJbmHNluo6BbCOaO6hOSPUqtyC_1wmWYJUwBPBbO5TiMULzXNVeAvd9donHLIY5xluLPKhWUi9Hwl_2Ng7rhU8q0z3ErKMW77H7rZMQ_-xzUAKw1giyrJ3Bq4zLSFKkO2Ra0ohIjQU2d27jg1Wrdp51gs-p7vH3ziE5oCTASsXUCdgpDtoO5KhDMQoAFHwzWS3B5JQtCrcfHSu3jodHoOUB38FSActOjJqtj9022kaw2Y08kURcYAxEXo_uCMq3ZD6wikj0mEypGbjhQzLmmbE09JTh3OLuGZb0YOzc-GM52XKJ5TwoOn8qWnPvj_RzxE11yvMEyUbaPN-WxhHgF0nMvHPtB_AyXFcG0 priority: 102 providerName: Wolters Kluwer Health |
Title | Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers |
URI | http://www.advbiores.net/article.asp?issn=2277-9175;year=2019;volume=8;issue=1;spage=63;epage=63;aulast=Sanaei;type=0 https://www.ncbi.nlm.nih.gov/pubmed/31737580 https://www.proquest.com/docview/2312771519 https://www.proquest.com/docview/2315528613 https://pubmed.ncbi.nlm.nih.gov/PMC6839273 https://doaj.org/article/d091d3176cb84466b2df4865856fa5aa |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELZgkxASQvwchVEZhMRTShM7jsMLdKNlQ-qEBoW-WbEdb4UuhaYV7L_nzkm7BTqJh6ZSfY2cu7P9XXz-jpAXXWZ5nHIe2DzlAbeJDiS4ThAZqQ3EB1Z7tv3hkTgY8Q_jeHyR_1QrsNwY2mE9qdF82vn98_wNDHjArx0edtmrTM878AEUGylkAN32e0WYxldD_WpWhpXW106L_K4lLJsVh-OGWzTWKE_l_--EfWnF-jub8tavGe50l999ovul5Wpwh9yucSbtVY5xl1zLi3vkxrDeSb9Pvnl-kCKn72BOzBfnAKLzkmaFpRsa6GFxOtETLMzzmg5XBXXpMMdjw5PyrKQzR3v-hASdFPQLxN-zZUn30aPm5QMyGvQ_7x8Edd2FwCRhPA0YY46JrtXSSTxxHjGWGG1cEuZCOmcgZGK5kzblEJ1Il2ojhYtFGmZ5am2o2UOyVUBHHxHKpbAJRHRCOMMdTK5JGHWlAcyZScdt2CLBStPK1KTkWBtjqiA4QcsotMqFZVrk5Vr-R0XHcaXkHhpuLYU02v6H2fxE1aNSWUBLFhCUMFrixraOrIMuQwglXBZnWYs8R7MrJMooMBPnJFuWpTr8dKx6IgTsBwA6hj7VQm4GfTdZfbABNIDcWg3J3YYkjGTTbF55l1oNBAX4G_wVcBk80bN1M_4Ts-OKHMyJMnEcSUBmLbJTOeP6ueHpGMSE3RZJGm7aUEyzpZicep5xgeA5gXu-bTi0OqsOal6heCWYqj1VrTz18X-r6Am5Cd9p9ZJrl2wt5sv8KcC-hW6T68k4gascvG-T7b3-0cfjtn-F0vYjHa5fWf8PD0xdRw |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkAAJIb4JDDAIxFNYEieOg4SgbEwrW_cAG-qbib-2wpaOptW0f4q_kbt8dA0w3vbQl_oSOXfnu9_ZvjtCXgTMxEkWx76xWezHJlW-ANXxIy2UhvjAqKra_mCHb-7Fn4bJcIn8anNh8FplaxMrQ23GGvfIVwGHRGkK_il7d_zTx65ReLrattCo1WLLnp5AyFa-7a-DfF9G0cbH3bVNv-kq4Gt4_NBnjDnGA6OEE5hPHTGWaqVdGlounNMQEDDrhMliwN7CZUoL7hKehbnNjAkVg_deIpdjPGKE9ZMO0_meTsDBmydZXRsyDgO2mqvJa_gBwI4kFvNZ8H1Vi4C_HcGCJ_zzlub1kzGeoJc_qgv0C25w4ya50eBX2qsV7hZZssVtcmXQnNDfId-ruiOFpetga-30FMC5LWleGPqPAdovDkZqhA1_3tBB26iXDiymI4_Ko5KOHe1VmRd0VNCvENePZyVdQ02dlHfJ3oVw_h5ZLmCiDwiNBTcpRIqcOx07MNppGAVCA5bNhYtN6BG_5bTUTbFz7LlxKCHoQclIlMqZZDzyak5_XJf5OJfyAwpuToXluas_xpN92ax2aQCFGUBmXCuBB-YqMg6mDKEZd3mS5x55jmKXWICjwBs--_msLGX_y2fZ4yFgSgDmCcypIXJjmLvOm4QJ4ADW7OpQrnQowULo7nCrXbKxUKU8W08eeTYfxifx1l1hQZxIkySRAMTnkfu1Ms6_G76OQawZeCTtqGmHMd2RYnRQ1S_nCMpTeOf7jkLLozoB9BzGS85ko6my1dSH__-yp-Tq5u5gW273d7YekWvAjKzePVshy9PJzD4GPDlVT6pFTMm3i7YavwF5oYs1 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Histone+Deacetylases+and+Histone+Deacetylase+Inhibitors%3A+Molecular+Mechanisms+of+Action+in+Various+Cancers&rft.jtitle=Advanced+biomedical+research&rft.au=Sanaei%2C+Masumeh&rft.au=Kavoosi%2C+Fraidoon&rft.date=2019-01-01&rft.pub=Medknow+Publications+and+Media+Pvt.+Ltd&rft.issn=2277-9175&rft.eissn=2277-9175&rft.volume=8&rft.issue=1&rft.spage=63&rft_id=info:doi/10.4103%2Fabr.abr_142_19&rft.externalDocID=A611720135 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2277-9175&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2277-9175&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2277-9175&client=summon |